symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TCRX,3.72,0.256499,108879,177885940,0,1.45-6.03,0.19,"TScan Therapeutics, Inc.",USD,0001783328,US89854M1018,89854M101,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.tscan.com,"TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.",Dr. Gavin  MacBeath Ph.D.,Healthcare,US,135,857 399 9500,830 Winter Street,Waltham,MA,02451,,0,https://financialmodelingprep.com/image-stock/TCRX.png,2021-07-16,False,False,True,False,False
